Overview
Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment
Status:
Terminated
Terminated
Trial end date:
2012-01-01
2012-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Recombinant human erythropoietin (r-HuEpo) has been used to treat renal anemia and improve morbidity and mortality in chronic kidney disease. Subcutaneous use of r-HuEpo causes immunogenicity and develops anti-r-HuEpo associated pure red cell aplasia (PRCA). The treatment of anti-r-HuEpo associated pure red cell aplasia is controversial. The investigators aim to evaluate the treatment for anti-r-HuEpo associated pure red cell aplasia in this study.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Chulalongkorn UniversityTreatments:
Cyclophosphamide
Cyclosporine
Cyclosporins
Epoetin Alfa
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mycophenolate mofetil
Mycophenolic Acid
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Criteria
Inclusion Criteria:- Age more than 18 years old
- CKD patient with anti-r-huEpo associated PRCA
Exclusion Criteria:
- Pregnancy or lactating women
- Receiving immunosuppression
- Active infection
- Previous history of allergic reaction to cyclosporine, mycophenolate mofetil,
cyclophosphamide, prednisolone